浅析雷替曲塞联合顺铂双途径化疗治疗老年晚期大肠癌患者临床效果.docVIP

精品论文 参考文献 浅析雷替曲塞联合顺铂双途径化疗治疗老年晚期大肠癌患者临床效果 马勇 (辽宁省葫芦岛市中心医院肿瘤科 125001) 【摘要】目的：探讨在老年晚期大肠癌患者中联用雷替曲塞及顺铂进行双途径化疗的临床疗效及安全性。方法：对2011~2013年我院收治的48例老年晚期大肠癌患者进行随机数字表法分组，每组24例，将其中实施雷替曲塞及顺铂进行静脉滴注化疗者归为对照组，将实施雷替曲塞静脉化疗＋顺铂腹腔灌注治疗者归为观察组，比较并评估两组的临床治疗结局，主要包括近期疗效、安全性等两个方面。结果：观察组治疗后可取得58.3%的近期疗效（包括CR 3例，PR 11例），较之对照组的20.8%更为理想，比较差异明显（P＜0.05）。在安全性方面，观察组治疗后有9例（37.5%）出现不适，与对照组的45.8%相对比略优，但比较差异不明显（P＞0.05）。结论：为老年晚期大肠癌患者提供雷替曲塞静脉化疗及顺铂腹腔灌注的双途径化疗法治疗，能够取得更为理想的临床疗效，且安全性相对可靠，适合在今后的临床上普及应用。 【关键词】雷替曲塞；顺铂；老年，晚期大肠癌 【中图分类号】R453 【文献标识码】A 【文章编号】1672-5085（2014）24-0035-02 On Raltitrexed dual pathways in combination with cisplatin in elderly patients with advanced clinical effects of chemotherapy in the treatment of colorectal cancer 【Abstract】Objective: To investigate in elderly patients with advanced colorectal cancer in combination with raltitrexed and cisplatin double chemotherapy clinical efficacy and safety. Methods: 2011 ~ 2013 in our hospital 48 cases of elderly patients with advanced colorectal cancer patients were randomly grouped, 24 cases in each group, which will be implemented raltitrexed and cisplatin infusion chemotherapy classified as the control group will be implemented Raltitrexed intravenous chemotherapy with cisplatin intraperitoneal treatment group classified as observation, comparison and evaluation of clinical outcomes between the two groups, including both short-term efficacy, safety, and so on. Results: After treatment available to 58.3% of short-term efficacy (including CR 3 例, PR 11 cases), compared with 20.8% in the control group even better, more significant differences (P lt;0.05). In terms of security, the observation group, 9 patients (37.5%) discomfort, and 45.8% in the control group relative ratio slightly better, but no significant difference (Pgt; 0.05). Conclusion: providing elderly patients with advanced colorectal cancer patients Raltitrexed intravenous chemotherapy and intrap